Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Hlds LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50p -0.64% 78.00p 76.00p 80.00p 78.50p 78.00p 78.50p 36,333.00 10:25:45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 44.2 -11.4 -6.0 - 406.65

Benchmark Hlds Share Discussion Threads

Showing 451 to 475 of 475 messages
Chat Pages: 19  18  17  16  15  14  13  12  11  10  9  8  Older
DateSubjectAuthorDiscuss
24/11/2016
09:20
Yes going to be a great share in 2017
nw99
24/11/2016
08:11
Ferd.no increase their holding by a million shares.
phowdo
22/11/2016
13:10
2m shs crossed
nw99
21/11/2016
21:39
About time. Couldn't see the trigger as such
hutch_pod
21/11/2016
20:14
Big volume pick up
nw99
21/11/2016
20:14
Big volume pick up
nw99
21/11/2016
09:33
loads of buying
larva
21/11/2016
09:06
in flight target 105p
larva
19/11/2016
17:24
Thanks for the info Miss Womble - that could well explain the share price rise and agree that there could be more to come in the short term... hxxps://theferret.scot/fish-farm-firm-kills-175000-salmon-accident Good luck all :)
multibagger
19/11/2016
10:49
Yesterday's price rise in Benchmark could be the response to the disaster that befell Marine Harvest on the Isle of Skye where tons of salmon were destroyed when a delicing procedure went wrong. Could go further on Monday
miss womble
18/11/2016
16:26
4 min to grab em for weekend
onjohn
18/11/2016
15:59
being quoted 8p over the price to buy a slab Buying 43,122 BENCHMARK HLDGS PLC ORD GBP0.001 shares The price quoted cannot be guaranteed until the order is confirmed. 10 Price £0.838695
larva
18/11/2016
15:56
news coming
larva
18/11/2016
15:22
i remember this went from 73p to 127p last time
larva
18/11/2016
15:22
i remember this went from 73p to 127p last time
larva
18/11/2016
15:21
Fly me prettys
larva
18/11/2016
14:49
going like the clappers
onjohn
18/11/2016
14:47
getting going now Someone bought 3 x10k INTERESTING
onjohn
18/11/2016
14:42
Hope so - one of my higher hopes for 2017 along with HZD (CURRENT DOG!)AND WSG (SERIAL NON DELIVERER)
cumbrian2
18/11/2016
14:38
Sneaky buying Weekend mention in Midas ? Will fly too 100p on Monday sooooooooo good
onjohn
09/11/2016
14:29
Looks to be finally breaking out of that trading range.
phowdo
26/10/2016
06:03
Trading Statement RNS Number : 4366N 26 October 2016 Benchmark Holdings plc ("Benchmark", the "Company" or the "Group") Trading Update and Notice of Results Benchmark, the aquaculture biotechnology and food chain sustainability business, announces that it expects Group performance for the year ended 30 September 2016 to be in line with the Board's expectations. The integration of INVE is on plan, with the key account management programme progressing well and work on the first co-developed products has commenced. The ongoing effect of El Niño in South East Asia and Latin America, and disease challenge coupled with low market prices in the shrimp sector, is resulting in delayed sector investment and lower growth rates in the short term in both regions. The Group intends to proceed cautiously with new investments until there is more visibility on early sales, whilst continuing to progress core infrastructure projects which support long term growth such as the state of the art vaccine facility at Braintree which is now entering the commissioning phase. The Group is focussing on growing sales and market share in developing markets, including China, for its Breeding and Genetics and Advanced Animal Nutrition Divisions, and is actively exploring routes to market and strategic relationships in those regions. The long term drivers of growth in the Company's sectors, which include the growing global demand for aquaculture products and an ever increasing pressure to limit the use of antibiotics in the food chain, are clearly positive. Benchmark offers an integrated package of both products and services to its customers, and they are increasingly recognising the significant value that this can deliver in terms of driving their productivity, sustainability and profitability. Benchmark expects to announce its full year results for the 12 months to 30 September 2016 on Tuesday, 24 January 2017. Commenting on trading, Benchmark's Chief Executive Officer, Malcolm Pye, said: "I am pleased to announce that the Group has delivered a solid performance in line with expectations, in a challenging but transformational year. We continue to execute our strategy to deploy world-leading technology through established distribution chains into long term growth markets, and our pipeline of products in development continues to progress well. "
multibagger
14/9/2016
10:21
If you would like to hear Malcolm Pye, Chief Executive Officer, provide an update on Benchmark he will be presenting at our next investor forum on the evening of Wednesday 28th of September. Also appearing will be the management of Venture Life Group plc and Vp plc. To learn more about the forum and to register for free please follow this link: https://www.eventbrite.co.uk/e/equity-development-investor-forum-september-2016-tickets-27428572599 Thanks, The Equity Development team
hannahh
31/8/2016
06:20
The IP acquisition juggernaut rolls on - targetting areas of unmet need in the equine healthcare sector, which by nature is generally well resourced and customers well heeled :) 31 August 2016 RNS Reach Benchmark Holdings plc ("Benchmark" or "the Company") Benchmark secures innovative new equine vaccine Benchmark is pleased to announce that its Animal Health division has entered into an agreement with Evax AG ("Evax"), a Swiss equine biotech company, to develop a recombinant vaccine to prevent and treat the most prevalent skin disease in horses, Sweet Itch, also known as Insect Bite Hypersensitivity (IBH). Sweet Itch is caused by an allergic immune response to Culicoides midge saliva. The disease poses a significant welfare challenge for horses through intense itching and biting which causes inflammation and often breaks the skin, allowing infection to set in. It affects 7.5% of the global horse population; the estimated total market value for treatment of the disease is over GBP100 million per annum. There is currently no efficacious preventative treatment or licensed vaccine available for controlling Sweet Itch in horses. The new vaccine utilises a Virus Like Particle technology (VLP), to which is attached a specific equine cytokine known to be implicated in this allergic disease. It combines the best of human science, cutting-edge technology and veterinary medicine to improve the quality of life of horses and horse owners. The Company expects the first commercialised product to be made available for the European, US and Canadian markets by 2020-21, followed by other markets. Under the terms of the agreement, Benchmark will pay total consideration of GBP1.12m and is contributing up to a further GBP4m over the next 4 years towards development, which will be conducted part in-house and part externally. Evax has granted Benchmark worldwide rights for sales, distribution and manufacturing of the product (excluding Switzerland) with royalties on net sales. Manufacturing will be performed at Benchmark's state-of-the-art Braintree site. The agreement adds a new product to the Company's vaccine portfolio and strengthens Benchmark's position to become a leader in providing veterinary allergy solutions for companion animals. Malcolm Pye, Chief Executive of Benchmark commented: "We are delighted to be partnering with such a highly-regarded team to develop this much needed solution for an issue which currently has no licensed vaccine treatment available. We continue to invest in cutting-edge technologies and are seeing further benefits from our investment in vaccine manufacturing at Braintree, where much of the development and all of the manufacturing for this vaccine will take place. "Our ability to collaborate with other teams in this technology space will enhance our own offering, both in the breadth of products we can provide and in improving the efficacy of our products currently in development." - ENDS -
multibagger
11/8/2016
06:07
Another strong addition to the IP portfolio and a new sector entry into shrimp breeding....excellent news ! Acq of South American shrimp breeding programme RNS Number : 8788G Benchmark Holdings PLC 11 August 2016 11 August 2016 Benchmark Holdings plc ("Benchmark" or "the Company") Acquisition of South American shrimp breeding programme Benchmark has entered into a technology transfer agreement under which its wholly-owned subsidiary, Genética Spring S.A.S, will secure control over aquaculture breeding programmes previously owned and operated by Centro de Investigación de la Acuicultura de Colombia Ceniacua (Ceniacua) and acquire related business, freehold land, buildings and assets, for a total consideration of $2.17m (£1.67m). Completion of the transaction is conditional upon certain legal formalities and is expected to occur before the end of August. The acquisition adds a third species, shrimp, to Benchmark's aquaculture breeding business in salmon and tilapia, and strengthens Benchmark's position in the fast-growing shrimp industry. Benchmark has a unique opportunity to utilise the global distribution channels within its Advanced Animal Nutrition division (INVE Aquaculture), which will provide routes to market for its shrimp genetics and offer opportunities for cross-selling. The acquired business, headquartered in Punta Canoa, near Cartagena in Colombia, operates breeding programmes for the species (L. vannamei) dominating the global shrimp sector, as well as for the marine finfish species cobia and grouper. The advanced shrimp selection programme has been particularly successful, and has bred populations with high level of resistance to certain of the major diseases affecting the shrimp industry worldwide. It is estimated that up to 40% of tropical shrimp production (>$3bn) is lost annually to disease, and according to the World Bank, production of farmed shrimp is expected to grow by 50 to 60% through to 20301. An experienced team of world-renowned scientists will join Genética Spring as part of this transaction. The team have a long standing relationship with Benchmark's Breeding & Genetics division, and the breeding programme will continue to benefit from the advanced genetic selection services offered by Benchmark's aquaculture genetics technology business Akvaforsk Genetics Center (AFGC). This existing relationship will also ensure smooth integration of the business into the Benchmark Group. Of the $2.17m total consideration approximately $1.33m relates to freehold land and buildings at Punta Canoa, and the balance to the breeding programme and other operational assets. Of the total consideration, US$0.35m is retained until such time as certain legal formalites related to the real estate are completed and US$0.57m is deferred, conditional upon specified operational milestones being achieved within 18 months of completion. Up to US$0.45m of the deferred consideration is payable in Benchmark shares, calculated by reference to the volume weighted average price (VWAP) of the Benchmark shares during the five business days which precede the final 3 business days prior to satisfaction of the deferred consideration. Benchmark has the option to settle this amount in cash. Management expect the acquisition to be significantly earnings enhancing from 2018. Commenting on the acquisition, Malcolm Pye, Chief Executive of Benchmark said: "This important acquisition strengthens our unique package of products and services that are urgently needed in the aquaculture industry today. It adds the third major aquaculture species shrimp to our already strong aquaculture breeding business in Salmon and Tilapia, and increases our market penetration into the fast-growing shrimp industry. There is strong and growing customer demand globally for disease resilient shrimp, which are more robust and deliver better yields. This acquisition provides us with very high calibre broodstock to meet that need, offering a substantial commercial opportunity for the Company and enhancing our growing reputation in aquaculture breeding and genetics."
multibagger
Chat Pages: 19  18  17  16  15  14  13  12  11  10  9  8  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20161205 04:30:01